Advertisement
Screener

Structure Therapeutics Inc. (GPCR) Increase Decrease In Operating Lease Liability

2.8 / 5 stars · 68/120 Roast Me

Structure Therapeutics Inc. Increase Decrease In Operating Lease Liability

Structure Therapeutics Inc. (GPCR) reported Increase Decrease In Operating Lease Liability of -$1.46 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-06

  • Structure Therapeutics Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$763.00K.
  • Structure Therapeutics Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$695.00K.
  • Structure Therapeutics Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$603.00K.
  • Structure Therapeutics Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$601.00K.
  • Structure Therapeutics Inc. increase decrease in operating lease liability for fiscal 2025 was -$2.30M.
  • Structure Therapeutics Inc. increase decrease in operating lease liability for fiscal 2024 was -$1.59M.
  • Structure Therapeutics Inc. increase decrease in operating lease liability for fiscal 2023 was -$315.00K.
  • Structure Therapeutics Inc. increase decrease in operating lease liability for fiscal 2022 was -$361.00K.
Period endIncrease Decrease In Operating Lease Liability 3 monthIncrease Decrease In Operating Lease Liability 6 monthIncrease Decrease In Operating Lease Liability 9 monthIncrease Decrease In Operating Lease Liability 12 month
2026-06-30-$763.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$1.46M
10-Q · filed 2026-08-06
-$2.06M
derived: sum of 3 quarters · filed 2026-08-06
-$2.66M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31-$695.00K
10-Q · filed 2026-05-07
-$1.30M
derived: sum of 2 quarters · filed 2026-05-07
-$1.90M
derived: sum of 3 quarters · filed 2026-05-07
-$2.53M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31-$603.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$1.20M
derived: sum of 2 quarters · filed 2026-02-26
-$1.84M
derived: sum of 3 quarters · filed 2026-08-06
-$2.30M
10-K · filed 2026-02-26
2025-09-30-$601.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$1.23M
derived: sum of 2 quarters · filed 2026-08-06
-$1.69M
10-Q · filed 2025-11-06
-$2.22M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30-$633.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$1.09M
10-Q · filed 2026-08-06
-$1.61M
derived: sum of 3 quarters · filed 2026-08-06
-$1.90M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31-$459.00K
10-Q · filed 2026-05-07
-$982.00K
derived: sum of 2 quarters · filed 2026-05-07
-$1.27M
derived: sum of 3 quarters · filed 2026-05-07
-$1.72M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31-$523.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$812.00K
derived: sum of 2 quarters · filed 2026-02-26
-$1.26M
derived: sum of 3 quarters · filed 2026-02-26
-$1.59M
10-K · filed 2026-02-26
2024-09-30-$289.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$740.00K
derived: sum of 2 quarters · filed 2025-11-06
-$1.07M
10-Q · filed 2025-11-06
-$1.14M
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30-$451.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06
-$779.00K
10-Q · filed 2025-08-06
-$850.00K
derived: sum of 3 quarters · filed 2026-02-26
-$907.00K
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31-$328.00K
10-Q · filed 2025-05-08
-$399.00K
derived: sum of 2 quarters · filed 2026-02-26
-$456.00K
derived: sum of 3 quarters · filed 2026-02-26
-$551.00K
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31-$71.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$128.00K
derived: sum of 2 quarters · filed 2026-02-26
-$223.00K
derived: sum of 3 quarters · filed 2026-02-26
-$315.00K
10-K · filed 2026-02-26
2023-09-30-$57.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13
-$152.00K
derived: sum of 2 quarters · filed 2024-11-13
-$244.00K
10-Q · filed 2024-11-13
-$328.00K
derived: sum of 4 quarters · filed 2024-11-13
2023-06-30-$95.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
-$187.00K
10-Q · filed 2024-08-08
-$271.00K
derived: sum of 3 quarters · filed 2024-08-08
-$371.00K
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31-$92.00K
10-Q · filed 2024-05-09
-$176.00K
derived: sum of 2 quarters · filed 2024-05-09
-$276.00K
derived: sum of 3 quarters · filed 2024-05-09
-$379.00K
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31-$84.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08
-$184.00K
derived: sum of 2 quarters · filed 2024-03-08
-$287.00K
derived: sum of 3 quarters · filed 2024-03-08
-$361.00K
10-K · filed 2024-03-08
2022-09-30-$100.00K
derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-11-17
-$203.00K
derived: sum of 2 quarters · filed 2023-11-17
-$277.00K
10-Q · filed 2023-11-17
2022-06-30-$103.00K
derived: 10-Q/A 6 month − 10-Q 3 month · filed 2023-11-17
-$177.00K
10-Q/A · filed 2023-11-17
2022-03-31-$74.00K
10-Q · filed 2023-05-11

Similar stocks

Stock NameCountryMarket CapPE Ratio
Spyre Therapeutics, Inc. (SYRE)United States$7.685B-43.69
Praxis Precision Medicines, Inc. (PRAX)United States$7.884B-27.60
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Alkermes plc. (ALKS)$6.844B132.74
RHYTHM PHARMACEUTICALS, INC. (RYTM)United States$6.771B-37.20
TG THERAPEUTICS, INC. (TGTX)United States$8.805B19.05
Protagonist Therapeutics, Inc (PTGX)United States$8.883B95.52
Liquidia Corp (LQDA)United States$6.347B51.23
Amneal Pharmaceuticals, Inc. (AMRX)$6.326B25.62
CYTOKINETICS INC (CYTK)United States$9.130B-11.86